Longer-acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue
Anna Coppola
Haemophilia, 2010
View PDFchevron_right
Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII - an open label, exploratory, cross-over, phase I/II study: FACTOR VIIA FORMULATED WITH PEGYLATED LIPOSOMES
Rivki Yatuv
Haemophilia, 2010
View PDFchevron_right
Infusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia A
Jack Spira
Haemophilia, 2008
View PDFchevron_right
Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes
Rivki Yatuv
Haemophilia, 2008
View PDFchevron_right
Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A
Sathy Balu-iyer
Journal of Pharmaceutical Sciences, 2008
View PDFchevron_right
Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A
Brigitt Abbuehl
Haemophilia, 2016
View PDFchevron_right
Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A
oleksandra stasyshyn
Blood, 2015
View PDFchevron_right
Current and evolving features in the clinical management of haemophilia
Anna Cerbone
Blood transfusion = Trasfusione del sangue, 2014
View PDFchevron_right
Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate
M. Schiavoni
Haemophilia, 2006
View PDFchevron_right
Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A
alejandra santiago
Haemophilia, 2015
View PDFchevron_right
Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia A
Pratima Chowdary
Journal of Blood Medicine, 2016
View PDFchevron_right
Use of recombinant factor VIII in the management of hemophilia
marco cattaneo
Current studies in hematology and blood transfusion, 1991
View PDFchevron_right
Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients
Brigitt Abbuehl
Haemophilia : the official journal of the World Federation of Hemophilia, 2016
View PDFchevron_right
Single-dose (270 μg kg −1 ) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres
Andrzej Mital
Haemophilia, 2009
View PDFchevron_right
The use of recombinant factor VIII in the management of Hemophilia
Alessandro Gringeri
La Ricerca in Clinica e in Laboratorio, 1991
View PDFchevron_right
Clinical Trial to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Recombinant Factor VIIa in Japanese Patients With Hemophilia With Inhibitors
Hideji Hanabusa
International Journal of Hematology, 2001
View PDFchevron_right
High dose of human plasma-derived FVIII-VWF as first-line therapy in patients affected by acquired haemophilia A and concomitant cardiovascular disease: four case reports and a literature review
E. Zanon
Haemophilia, 2013
View PDFchevron_right
Cross‐sectional comparative study of pharmacokinetics and efficacy between sucrose‐formulated recombinant factor VIII (Kogenate ® ) and BAY 81‐8973 (Kovaltry ® ) in patients with severe or moderate haemophilia A in prophylaxis
José luis Poveda
Haemophilia, 2019
View PDFchevron_right
Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study
FRANCESCO DEMARTIS
Haemophilia, 2017
View PDFchevron_right
Once‐weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8‐GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)
Nicola Curry
Haemophilia, 2019
View PDFchevron_right
Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy
K. Hoots
Thrombosis and Haemostasis, 2000
View PDFchevron_right
New opportunities in Haemophilia treatment: Efmoroctocog Alfa for patients with Haemophilia A
Carlo Favaretti
Epidemiology, Biostatistics, and Public Health
View PDFchevron_right
Factor VIII therapy for hemophilia A: current and future issues
Kenneth Mann
Expert review of hematology, 2014
View PDFchevron_right
Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
Babu Subramanyam
Blood, 2010
View PDFchevron_right
Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors
Davide Matino, Alfonso Iorio
Protocols, 1996
View PDFchevron_right
Special lectures in haemophilia management
Angelika Batorova
Haemophilia, 2010
View PDFchevron_right
ReFacto� and Advate� 2 : a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A
Craig Kessler
Haemophilia, 2007
View PDFchevron_right
40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors
Per Arkhammar
Journal of Thrombosis and Haemostasis, 2013
View PDFchevron_right
Adjusted dose continuous infusion of factor VIII in patients with haemophilia A
Shari Gitel
British Journal of Haematology, 1992
View PDFchevron_right
Pharmacokinetics of a new human plasma‐derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients
Valentina Uscatescu
Haemophilia, 2019
View PDFchevron_right